Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Author:

Kaczmarek Radoslaw1ORCID,El Ekiaby Magdy12,Hart Daniel P.134,Hermans Cedric15,Makris Mike16ORCID,Noone Declan17,O’Mahony Brian189ORCID,Page David110ORCID,Peyvandi Flora11112ORCID,Pipe Steven W.11314ORCID,Sannié Thomas1715ORCID,Schlenkrich Uwe116,Skinner Mark W.11718ORCID,Srivastava Alok119ORCID,Bok Amanda7,Pierce Glenn F.120ORCID,

Affiliation:

1. Coagulation Product Safety, Supply and Access Committee World Federation of Hemophilia Montreal Quebec Canada

2. Shabrawishi Hospital Blood Transfusion & Hemophilia Treatment Center Giza Egypt

3. The Royal London Hospital Haemophilia CentreBarts Health NHS Trust London UK

4. Centre for Immunobiology Blizard InstituteBarts and The London School of Medicine and DentistryQMUL London UK

5. Hemostasis and Thrombosis Unit Division of Hematology Cliniques Universitaires Saint‐LucUCLouvain Brussels Belgium

6. Medical Advisory Group European Haemophilia Consortium Brussels Belgium

7. European Haemophilia Consortium Brussels Belgium

8. Irish Haemophilia Society Dublin Ireland

9. Trinity College Dublin Ireland

10. Canadian Hemophilia Society Montreal Canada

11. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

12. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

13. Medical and Scientific Advisory Council National Hemophilia Foundation New York NY USA

14. Departments of Pediatrics and Pathology University of Michigan Ann Arbor MI USA

15. Association Française des Hémophiles Paris France

16. German Haemophilia Society Hamburg Germany

17. Institute for Policy Advancement Ltd Washington DC USA

18. McMaster University Hamilton Ontario Canada

19. Department of Haematology Christian Medical College Vellore India

20. World Federation of Hemophilia Montreal Quebec Canada

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Reference18 articles.

1. Three decades of messenger RNA vaccine development

2. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials

3. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

5. Moderna’s COVID‐19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna Inc.https://investors.modernatx.com/news‐releases/news‐release‐details/modernas‐covid‐19‐vaccine‐candidate‐meets‐i

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3